Genomics Market Check: Survey on Budgets, Innovation and Platform Preferences

Research evidence excerpt

Genomics Market Check: Survey on Budgets, Innovation and Platform Preferences

USA | Life Science Tools & Diagnostics EquityJulyResearch12, 2026

Exhibit 1 - 10x appears best positioned toGenomics Market Check: Survey on Budgets,

capture incremental perturb-seq project share

as interest builds (26% currently use or plan toInnovation and Platform Preferences

adopt perturb-seq)

We conducted a survey (n=50) to better understand appetites in the sequencing

and single cell/spatial markets. Takeaways: 1) 10x remains dominant in single

cell/spatial and is best positioned to capture perturb-seq projects (20% will

adopt in future); 2) NovaSeq X has runway remaining from switches (34% will

transition from 6000 in a year) and 72% like the 18-month roadmap; and 3)

Roche Axelios features (chip re-use, speed) are less appealing than anticipated.

.

Source: JEF Survey Data

Background. We recently surveyed (n=50) lab managers responsible for purchasing sequencing

instruments and consumables for bulk NGS, single-cell and spatial analysis. The majority of Exhibit 2 - NovaSeq X adoption remains a

respondents came from biopharma (86%) followed by core labs (6%), CRO/CDMO's (4%) and multi-year replacement cycle, with meaningful

demand (34%) still aheadacademic labs (4%), with the total pool >$400M in annual sequencing budgets. Results were

collected from 6/24-6/30.

State of play in bulk NGS. ILMN maintains a significant edge in bulk NGS with 49/50 respondents

noting ownership of at least one instrument (61% listed NovaSeq as primary instrument). 34% of

respondents intend to migrate from NovaSeq 6000 to X in the next year, while 72% noted that ILMN's

18-month roadmap (higher output, Q70, staggered starts) increases the likelihood of remaining

on NovaSeq.